-- Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.7%.
The iShares Biotechnology ETF (IBB) dropped 1.4%.
In corporate news, Gilead Sciences (GILD) could beat Q1 consensus estimates, but weaker-than-expected persistence rates for Yeztugo point to a potential risk to long-term peak sales for the HIV pre-exposure prophylaxis drug, RBC Capital Markets said in a note. Gilead shares were down 0.9%.